Corbus Pharmaceuticals Files 8-K on Financials
Ticker: CRBP · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1595097
Sentiment: neutral
Topics: financial-condition, operations, disclosure
Related Tickers: CRBP
TL;DR
CRBP filed an 8-K on Nov 12, 2025, detailing financial results and operations.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on November 12, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company, incorporated in Delaware, is located at 500 River Ridge Drive, Norwood, Massachusetts.
Why It Matters
This 8-K filing provides an update on Corbus Pharmaceuticals' financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- November 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 500 River Ridge Drive, Norwood, Massachusetts 02062 (address) — Principal Executive Offices
- SAV Acquisition Corp (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Corbus Pharmaceuticals Holdings, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements.
When was this 8-K report filed?
This 8-K report was filed on November 12, 2025.
What is Corbus Pharmaceuticals Holdings, Inc.'s state of incorporation?
Corbus Pharmaceuticals Holdings, Inc. is incorporated in Delaware.
Where are Corbus Pharmaceuticals Holdings, Inc.'s principal executive offices located?
The principal executive offices of Corbus Pharmaceuticals Holdings, Inc. are located at 500 River Ridge Drive, Norwood, Massachusetts 02062.
Was Corbus Pharmaceuticals Holdings, Inc. previously known by another name?
Yes, Corbus Pharmaceuticals Holdings, Inc. was formerly known as SAV Acquisition Corp.
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-11-12 08:14:37
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
Filing Documents
- crbp-20251112.htm (8-K) — 48KB
- crbp-ex99_1.htm (EX-99.1) — 245KB
- 0001193125-25-276062.txt ( ) — 419KB
- crbp-20251112.xsd (EX-101.SCH) — 31KB
- crbp-20251112_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. Corbus Pharmaceuticals Holdings, Inc. (the "Company") issued a press release on November 12, 2025, disclosing financial information and operating metrics for its fiscal quarter ended September 30, 2025 and discussing its business outlook. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. See "Item 2.02 Results of Operations and Financial Condition" above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) The following exhibit is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated November 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: November 12, 2025 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer